Center-Authored Papers

Filters: Author is Green, Damian J  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
B
Balkin ER, Kenoyer A, Orozco JJ, Hernandez A, Shadman M, Fisher DR, Green DJ, Hylarides MD, Press OW, Wilbur SD et al..  2014.  In vivo localization of 90Y and 177Lu radioimmunoconjugates using Cerenkov luminescence imaging in a disseminated murine leukemia model.. Cancer research. 74(20):5846-54. Abstract
Bensinger WI, Green DJ, Burwick N, Becker PS.  2014.  A prospective study of lenalidomide monotherapy for relapse after Allo-SCT for multiple myeloma.. Bone marrow transplantation. 49(4):492-5. Abstract
Budde LE, Guthrie KA, Till BG, Press OW, Chauncey TR, Pagel JM, Petersdorf SH, Bensinger WI, Holmberg L, Shustov AR et al..  2011.  Mantle cell lymphoma international prognostic index but not pretransplantation induction regimen predicts survival for patients with mantle-cell lymphoma receiving high-dose therapy and autologous stem-cell transplantation.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 29(22):3023-9. Abstract
C
Cassaday RD, Guthrie KA, Budde EL, Thompson L, Till BG, Press OW, Chauncey TR, Pagel JM, Petersdorf SH, Palanca-Wessels MC et al..  2013.  Specific features identify patients with relapsed or refractory mantle cell lymphoma benefitting from autologous hematopoietic cell transplantation.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 19(9):1403-6. Abstract
Cassaday RD, Stevenson PA, Gooley TA, Chauncey TR, Pagel JM, Rajendran J, Till BG, Philip M, Orozco JJ, Bensinger WI et al..  2015.  High-dose CD20-targeted radioimmunotherapy-based autologous transplantation improves outcomes for persistent mantle cell lymphoma.. British journal of haematology. 171(5):788-97. Abstract
Cassaday RD, Storer BE, Sorror ML, Sandmaier BM, Guthrie KA, Maloney DG, Rajendran JG, Pagel JM, Flowers ME, Green DJ et al..  2015.  Long-term outcomes of patients with persistent indolent B cell malignancies undergoing nonmyeloablative allogeneic transplantation.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 21(2):281-7. Abstract
Cowan AJ, Klippel ZK, Stevenson PA, Hyun TS, Tuazon S, Becker PS, Green DJ, Holmberg LA, Coffey DG, Gopal AK et al..  2016.  Pre-transplantation novel agent induction predicts progression-free survival for patients with immunoglobulin light-chain amyloidosis undergoing high-dose melphalan and autologous stem cell transplantation.. Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis. 23(4):254-259. Abstract
Cowan AJ, Stevenson PA, Gooley TA, Frayo SL, Oliveira GR, Smith SD, Green DJ, Roden JE, Pagel JM, Wood BL et al..  2017.  Results of a phase I-II study of fenretinide and rituximab for patients with indolent B-cell lymphoma and mantle cell lymphoma.. British journal of haematology. Abstract
Cowan AJ, Frayo SL, Press OW, Palanca-Wessels MC, Pagel JM, Green DJ, Gopal AK.  2015.  Bortezomib and fenretinide induce synergistic cytotoxicity in mantle cell lymphoma through apoptosis, cell-cycle dysregulation, and IκBα kinase downregulation.. Anti-cancer drugs. 26(9):974-83. Abstract
F
Fong DL, Murnane RD, Hotchkiss CE, Green DJ, Hukkanen RR.  2011.  Pulmonary embolization of fat and bone marrow in cynomolgus Macaques (Macaca fascicularis).. Comparative medicine. 61(1):86-91. Abstract
Frost SHL, Frayo SL, Miller BW, Orozco JJ, Booth GC, Hylarides MD, Lin Y, Green DJ, Gopal AK, Pagel JM et al..  2015.  Comparative efficacy of 177Lu and 90Y for anti-CD20 pretargeted radioimmunotherapy in murine lymphoma xenograft models.. PloS one. 10(3):e0120561. Abstract
G
Gopal AK, Tarantolo SR, Bellam N, Green DJ, Griffin M, Feldman T, Mato AR, Eisenfeld AJ, Stromatt SC, Goy A.  2014.  Phase 1b study of otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR™ therapeutic protein, in combination with rituximab and bendamustine in relapsed indolent lymphoma patients.. Investigational new drugs. 32(6):1213-25. Abstract
Green DJ, Orgun NN, Jones JC, Hylarides MD, Pagel JM, Hamlin DK, Wilbur DS, Lin Y, Fisher DR, Kenoyer AL et al..  2014.  A Preclinical Model of CD38-Pretargeted Radioimmunotherapy for Plasma Cell Malignancies.. Cancer research. 74(4):1179-89. Abstract
Green DJ, Pagel JM, Nemecek ER, Lin Y, Kenoyer A, Pantelias A, Hamlin DK, Wilbur SD, Fisher DR, Rajendran JG et al..  2009.  Pretargeting CD45 enhances the selective delivery of radiation to hematolymphoid tissues in nonhuman primates.. Blood. 114(6):1226-35. Abstract
Green DJ, Shadman M, Jones JC, Frayo SL, Kenoyer AL, Hylarides MD, Hamlin DK, Wilbur SD, Balkan ER, Lin Y et al..  2015.  Astatine-211 conjugated to an anti-CD20 monoclonal antibody eradicates disseminated B-cell lymphoma in a mouse model.. Blood. 125(13):2111-9. Abstract
Green DJ, Bensinger WI.  2017.  A View from the Plateau: Is There a Role for Allogeneic Stem Cell Transplantation in the Era of Highly Effective Therapies for Multiple Myeloma? Current hematologic malignancy reports. Abstract
Green DJ, Frayo SL, Lin Y, Hamlin DK, Fisher DR, Frost SHL, Kenoyer AL, Hylarides MD, Gopal AK, Gooley TA et al..  2016.  Comparative analysis of bispecific antibody and streptavidin-targeted radioimmunotherapy for B cell cancers.. Cancer research. Abstract
Green DJ, Pagel JM, Pantelias A, Hedin N, Lin Y, Wilbur SD, Gopal A, Hamlin DK, Press OW.  2007.  Pretargeted radioimmunotherapy for B-cell lymphomas.. Clinical cancer research : an official journal of the American Association for Cancer Research. 13(18 Pt 2):5598s-5603s. Abstract
Green DJ, Press OW.  2017.  Whither Radioimmunotherapy: To Be or Not To Be? Cancer research. 77(9):2191-2196. Abstract
L
Libby EN, Becker PS, Burwick N, Green DJ, Holmberg L, Bensinger WI.  2015.  Panobinostat: a review of trial results and future prospects in multiple myeloma.. Expert review of hematology. 8(1):9-18. Abstract
M
Mawad R, Gooley TA, Rajendran JG, Fisher DR, Gopal AK, Shields AT, Sandmaier BM, Sorror ML, Deeg HJ, Storb R et al..  2014.  Radiolabeled Anti-CD45 Antibody with Reduced-Intensity Conditioning and Allogeneic Transplantation for Younger Patients with Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 20(9):1363-8. Abstract
Miller BW, Frost SHL, Frayo SL, Kenoyer AL, Santos E, Jones JC, Green DJ, Hamlin DK, Wilbur SD, Fisher DR et al..  2015.  Quantitative single-particle digital autoradiography with α-particle emitters for targeted radionuclide therapy using the iQID camera.. Medical physics. 42(7):4094. Abstract
N
Nemecek ER, Green DJ, Fisher DR, Pagel JM, Lin Y, Gopal AK, Durack LD, Rajendran JG, Wilbur SD, Nilsson R et al..  2008.  Extracorporeal adsorption therapy: a method to improve targeted radiation delivered by radiometal-labeled monoclonal antibodies.. Cancer biotherapy & radiopharmaceuticals. 23(2):181-91. Abstract
O
O'Steen S, Green DJ, Gopal AK, Orozko JJ, Kenoyer AL, Lin Y, Wilber SD, Hamlin DK, Fisher DR, Hylarides MD et al..  2017.  Venetoclax Synergizes with Radiotherapy for Treatment of B cell Lymphomas.. Cancer research. 77(14):3885-3893. Abstract
Onishi M, Graf SA, Holmberg L, Behnia S, Shustov AR, Schiavo K, Philip M, Libby EN, Cassaday RD, Pagel JM et al..  2015.  Brentuximab vedotin administered to platinum-refractory, transplant-naïve Hodgkin lymphoma patients can increase the proportion achieving FDG PET negative status.. Hematological oncology. 33(4):187-191. Abstract